A novel bispecific antibody targeting TNF-α and IL-6 receptor as a potent immunotherapeutic agent for inflammation.

ABSTRACT: Tumor necrosis factor-alpha and interleukin-6 are proinflammatory cytokines involved in several autoimmune diseases, including rheumatoid arthritis. Although monoclonal antibodies targeting these cytokines or their receptors are successful treatment approaches for autoimmune diseases, approximately 30% of treated patients fail to respond. Therefore, the designation of more effective and versatile therapeutics for simultaneously targeting multiple inflammatory pathways is pivotal. This study aimed to design a recombinant bispecific antibody (BisAb) targeting TNF-α and IL-6 receptor based on the complementarity-determining regions (CDRs) of adalimumab and tocilizumab antibodies. The physicochemical properties and tertiary structure of the modeled bispecific antibody proteins were studied thr

SUBMITTER: Heravi M 

PROVIDER: S-EPMC12511189 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature